KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.95

Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial.

Frank A Vicini, Kathryn Winter, Gary M Freedman, Douglas W Arthur, Barry S Rosenstein, Soren M Bentzen, X Allen Li, Michele Y Halyard, Wendy A Woodward, Richard J Bleicher, Alphonse Taghian, Janice Lyons, Janice K Tomberlin, Samantha A Seaward, Sally B Cheston, Andrew C Hoover, Bethany M Anderson, Francisco E Perera, Matthew M Poppe, Ivy A Petersen, Sachin Jhawar, Tarek Hijal, Jennifer Moughan, Benjamin Movsas, Julia R White

J Clin Oncol 44(19) 1798-1811

PMID42114027
PMCIDPMC13166090
DOI10.1200/JCO-25-02465
发表日期2026-05-11
入排依据:Study is a Phase III randomized trial with time-to-event endpoints (IBR, DFS, OS) and reports primary results, but the intervention compares radiation therapy regimens and does not include a drug-containing intervention.
摘要

摘要

PURPOSE: For patients with breast cancer undergoing breast conservation, escalating the dose (boost) of radiation to the lumpectomy cavity after whole-breast irradiation (WBI) reduces ipsilateral breast recurrence (IBR) but extends treatment duration. This phase III trial investigated whether boost delivery during WBI versus after WBI provides noninferior IBR and preserves cosmetic appearance. METHODS: NRG/RTOG 1005 randomly assigned patients at higher risk for IBR after lumpectomy and axillary surgery to either a sequential boost of 12 Gy in six fractions(F) or 14 Gy in 7F after WBI of 50 Gy in 25F or 42.7 Gy in 16F (sequential arm) or a concurrent boost of 8 Gy in 15F of 0.53 Gy per day with WBI of 40 Gy in 15F (concurrent arm) using 3-dimensional conformal radiation therapy (RT) or intensity-modulated RT. Based on 1.59% 5-year IBR for the sequential arm, defining the noninferiority margin as a hazard ratio upper limit on the 90% CI of 2.12, 2,312 patients provide 80% power for noninferiority of IBR as first recurrence for the concurrent arm. Secondary end points included disease-free survival and overall survival, adverse events (AEs), and cosmetic outcomes. RESULTS: Between May 24, 2011, and June 20, 2014, 2,354 patients were randomly assigned, with 2,255 eligible for analysis (sequential arm, n = 1,118; concurrent arm, n = 1,137). With median follow-up of 7.3 years, there were 56 IBR events; 5- and 7-year IBR were 2.1% and 2.2% on the sequential arm and 1.9% and 2.6% on the concurrent arm, respectively. The noninferiority criterion was met: HR (90% CI): 1.31 (0.84 to 2.04), P = .037. No differences were observed in AEs, cosmetic outcomes, or survival between arms. CONCLUSION: Concurrent boost during WBI results in noninferior IBR compared with sequential boost without worsening toxicity or cosmetic outcomes and reduces overall treatment time.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2:

Ipsilateral breast recurrence Abbreviations: HR, hazard ratio; CI, confidence interval; RL, reference level

In-Breast_Recurrence

Ipsilateral breast recurrence

Figure 2: · Panel In-Breast_Recurrence

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel In-Breast_Recurrence 是同一 Figure 2: 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1:Consort Flow Diagram Abbreviations: QoL, quality of life
非 KM Figure
Figure 3:Mean change of Patient-Reported BCTOS cosmetic, breast pain, function, and edema subscales by treatment arm across collection times Abbreviations: RT, RTRT
非 KM Figure